Literature DB >> 16555293

Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B.

D Sprengers1, R G van der Molen, J G Kusters, B Hansen, H G M Niesters, S W Schalm, H L A Janssen.   

Abstract

Based on virological and biochemical parameters patients with chronic hepatitis B virus (HBV) are divided into distinct clinical phases: the immune-tolerance phase, the immune-clearance phase, and the inactive carrier state. Unclear is whether these phases have characteristic intrahepatic immune responses. The composition of liver-derived lymphocytes in patients with chronic HBV infection was studied. In 47 patients the composition of liver-derived lymphocytes was analyzed by flow cytometry of fine needle aspiration biopsies of the liver. The proportion natural killer (NK) cells in the liver was significantly higher in immune-tolerant than in immune-clearance patients and inactive carriers. No differences were found in proportion CD4+ T-cells and CD8+ T-cells, in these phases. However, when patients in the immune-clearance phase, with similar alanine transaminase (ALT), were grouped according to viral load, the proportion CD8+ T-cells was higher in those with high viral load. In contrast, the proportion CD4+ T-cells was increased in patients with low HBV-DNA. These differences were absent in the peripheral blood (PB). Intrahepatic HBV-specific CD8+ T-cells were mainly found in immune-clearance patients with low viral load. In conclusion, clear differences in the intrahepatic cellular infiltrate were found between the various clinical phases of chronic HBV infection. These findings are relevant to the design of new, individualized anti-viral strategies. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555293     DOI: 10.1002/jmv.20576

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

1.  Role natural killer group 2D-ligand interactions in hepatitis B infection.

Authors:  Teresa Pollicino; Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-04-28

Review 2.  Immune restoration diseases reflect diverse immunopathological mechanisms.

Authors:  Patricia Price; David M Murdoch; Upasna Agarwal; Sharon R Lewin; Julian H Elliott; Martyn A French
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

3.  PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.

Authors:  Chang-Long Chen; Qiu-Zhong Pan; Jing-Jing Zhao; Ying Wang; Yong-Qiang Li; Qi-Jing Wang; Ke Pan; De-Sheng Weng; Shan-Shan Jiang; Yan Tang; Xiao-Fei Zhang; Hong-Xia Zhang; Zi-Qi Zhou; Yi-Xin Zeng; Jian-Chuan Xia
Journal:  Oncoimmunology       Date:  2016-05-31       Impact factor: 8.110

4.  Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Authors:  Christina M Martin; Jeffrey A Welge; Norah J Shire; Mohamed T Shata; Kenneth E Sherman; Jason T Blackard
Journal:  Cytokine       Date:  2009-07-21       Impact factor: 3.861

5.  Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load.

Authors:  Jing You; Lin Zhuang; Yi-Feng Zhang; Hong-Ying Chen; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Teerha Piratvisuth; Edward McNeil; Lan Yu; Bao-Zhang Tang; Jun-Hua Huang
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

Review 6.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.

Authors:  J Judy Chang; Sunee Sirivichayakul; Anchalee Avihingsanon; Alex J V Thompson; Peter Revill; David Iser; John Slavin; Supranee Buranapraditkun; Pip Marks; Gail Matthews; David A Cooper; Stephen J Kent; Paul U Cameron; Joe Sasadeusz; Paul Desmond; Stephen Locarnini; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

8.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.

Authors:  Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

9.  NK cells: a double-edged sword in chronic hepatitis B virus infection.

Authors:  Mala K Maini; Dimitra Peppa
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

10.  A synergistic interferon-gamma production is induced by mouse hepatitis virus in interleukin-12 (IL-12)/IL-18-activated natural killer cells and modulated by carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1a receptor.

Authors:  Alexandre Jacques; Christian Bleau; Claire Turbide; Nicole Beauchemin; Lucie Lamontagne
Journal:  Immunology       Date:  2008-12-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.